Ritonavir Boosting of low-dose Roche HCV Protease Inhibitor RG7227 ITMN-191

Ritonavir Boosting of low-dose Roche HCV Protease Inhibitor RG7227 ITMN-191 Results in Robust Reduction in HCV RNS at Lowr Exposures than provided by unboosted regimens - see attached full poster report


Reported by Jules Levin
EASL Apr 14-18 2010 Vienna Austria

AUTHOR CONCLUSIONS

RTV boosting of low dose danoprevir achieves potent antiviral activity
-- Increased proportion of undetectable HCV RNA (50-100%) and steeper beta phase slope as compared to historic data obtained with unboosted 900 mg BID danoprevir

Danoprevir/r + SOC was safe and well tolerated over 15 days of treatment without evidence of hepatotoxicity

Danoprevir AUC and Cmax parameters, which are often correlated with safety, for danoprevir/r regimens are substantially lower than unboosted regimen

Potential impact of lower exposure on long-term safety and tolerability needs to be studied

Future clinical trials of danoprevir will be conducted with ritonavir boosted dosing